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Rationale: Recent evidence suggests that Obstructive Sleep Apnea (OSA) may be a risk factor 59 
for developing Mild Cognitive Impairment and Alzheimer’s disease. However, how sleep apnea 60 
affects longitudinal risk for Alzheimer’s disease is less well understood. 61 
 62 
Objective: To test the hypothesis that there is an association between severity of OSA and 63 
longitudinal increase in amyloid burden in cognitively normal elderly.  64 
 65 
Methods: Data was derived from a 2-year prospective longitudinal study that sampled 66 
community-dwelling healthy cognitively normal elderly. Subjects were healthy volunteers between 67 
the ages of 55 to 90, were non-depressed and had a consensus clinical diagnosis of cognitively 68 
normal. CSF Amyloid beta was measured using ELISA. Subjects received Pittsburgh compound 69 
B Positron Emission Tomography scans following standardized procedures. Monitoring of OSA 70 
was completed using a home sleep recording device. 71 
 72 
Measurements and Main Results: We found that severity of OSA indices (lnAHIall [F1,88=4.26, 73 
p<.05] and lnAHI4% [F1,87=4.36, p<.05])  were associated with annual rate of change of CSF Aβ42 74 
using linear regression after adjusting for age, sex, BMI and ApoE4 status. LnAHIall and lnAHI4 75 
were not associated with increases in ADPiB-mask most likely due to the small sample size 76 
although there was a trend for lnAHIall (F1,28=2.96, p=.09 and F1,28=2.32, n.s. respectively). 77 
 78 
Conclusion: In a sample of cognitively normal elderly, OSA was associated with markers of 79 
increased amyloid burden over the 2 year follow-up. Sleep fragmentation and/or intermittent 80 
hypoxia from OSA are likely candidate mechanisms. If confirmed, clinical interventions for OSA 81 






At a Glance Commentary: 88 
Scientific knowledge on the subject: Recent literature in both mice and humans suggests that 89 
disturbed sleep leads to higher levels of brain soluble beta amyloid peptides, which aggregates 90 
to forms senile plaques, a hallmark of Alzheimer’s disease. This pathological process might be 91 
present prior to cognitive decline, indicating that disturbed sleep can be both a consequence and 92 
a risk factor for Alzheimer’s disease. 93 
What this study adds to the field: This longitudinal study shows that obstructive sleep apnea, 94 













































Obstructive Sleep Apnea (OSA) and Alzheimer’s disease (AD) are both chronic disease 101 
conditions that are highly prevalent, cause significant morbidity and mortality to those afflicted,1;2 102 
and have an enormous socio-economic impact. OSA is typified by recurrent partial or complete 103 
obstructions of the upper airway during sleep leading to intermittent hypoxia and/or sleep 104 
fragmentation. OSA is associated with hypertension, cardiovascular risk, cognitive decline3 and 105 
multiple inflammatory and metabolic effects4-6  (for a review see7). OSA affects up to 30-80% of 106 
the elderly8;9 depending on how OSA is defined. The clinical relevance of these high rates in the 107 
elderly is unclear, as some studies demonstrate increased rates of mortality, while others suggest 108 
that sleepiness, cognitive impairment, hypertension and mortality associated with OSA decline 109 
with age.10 However, in a recent study of older women where nocturnal polysomnography was 110 
collected at baseline and cognition was evaluated 5 years later, OSA patients were more likely to 111 
develop mild cognitive impairment (MCI) or dementia at follow-up.3 In a similar study using the 112 
Alzheimer’s Disease Neuroimaging Initiative (ADNI) database, we found that reported OSA 113 
patients had an earlier age of cognitive decline to MCI and to AD than non-OSA controls.11 114 
Furthermore, in a meta-analysis of cross-sectional studies, patients with AD were five times more 115 
likely to present with OSA than cognitively unimpaired individuals of similar age.12 While OSA 116 
could be a consequence of events in the progression of AD pathology, alternatively, OSA may 117 
precipitate AD pathogenesis. The latter would present an exciting opportunity to slow AD 118 
pathology with sleep interventions.  119 
The link between severity of OSA and risk for AD could be mediated by an increase in amyloid 120 
deposition as a small number of cross-sectional studies suggest. Greater Aβ burden using 121 
amyloid-PET, globally and regionally in the precuneus has been associated with OSA severity 122 
among MCI patients.13 We also demonstrated a trend toward decreased cerebrospinal fluid (CSF) 123 
amyloid beta 42 (Aβ42) levels in cognitively normal ApoE4+ carriers with OSA,14 and a recent 124 
cross-sectional study showed that OSA patients had lower CSF Aβ42 levels when compared to 125 
controls,15 suggesting that OSA might contribute to amyloid deposition and accelerate cognitive 126 
decline in those at risk for AD. However, so far it has been challenging to verify causality for these 127 
associations as OSA and AD may share common risk factors16;17 as well as neurodegenerative 128 
consequences17 (e.g. vascular damage, hippocampal atrophy). 129 
Based on the existing literature, the aims of this study were to use the NYU Center for Brain 130 
Health (CBH) cohort of cognitively normal healthy elderly to investigate the cross-sectional and 131 
longitudinal associations between OSA severity and changes in CSF and PET biomarkers of AD. 132 
METHODS: 133 
NYU Cohort: 134 
The NYU cohort consists of community-dwelling healthy cognitively normal volunteers and was 135 
derived from 3 NIH/NIA and 1 Alzheimer’s Association supported studies. All subjects received 136 
medical, neurological, and psychiatric evaluations, clinical labs, home monitoring for OSA, 137 
structural magnetic resonance imaging (MRI) scans, a lumbar puncture (LP) and/or a Pittsburgh 138 
compound B (PiB) PET scan. As such, sleep complaints were not part of the inclusion or exclusion 139 
criteria of these protocols nor were subjects referred to the studies from any sleep disorders clinic. 140 
All subjects were administered a standard neuropsychological test battery which has published 141 
norm values.18 142 
Subjects: 143 
Subjects were between the ages of 55 to 90, English speaking, with a minimum of 12 years of 144 
education, had Mini-Mental State Exam (MMSE)19 scores between 25–30 (inclusive), a Clinical 145 









































cognitively normal. Due to known CSF batch variations, only values that were either batch 147 
corrected or from the same assay date were included. Individuals using continuous positive 148 
airway pressure (CPAP) or with significant medical conditions that could affect brain structure or 149 
function and/or MRI evidence of intracranial mass or infarcts were excluded. Written informed 150 
consent was obtained from all participants. 151 
 152 
Sleep Evaluation: 153 
The sleep evaluation included a sleep interview, detailed snoring history, and self-154 
administration of the Epworth Sleepiness Scale (ESS).21 Home monitoring of OSA was completed 155 
using either an “ARES” Unicorder (Watermark)22 or an “Embletta MPR” (Natus Medical Inc.)23 156 
system during a 2-night period. For most subjects, home sleep evaluations were completed prior 157 
to the baseline lumbar puncture (LP) and amyloid PET scan. However, there were few subjects 158 
(n=21) whose sleep evaluations were done after the baseline LP and amyloid PET scan. Out of 159 
these 21 subjects only 5 completed their follow-up LP and amyloid PET scan of whom were 160 
included in the longitudinal analyses. The variables used in this study were: (1) the 161 
apnea/hypopnea index with 4% desaturation (AHI4%), defined as the sum of all apneas (>90% 162 
reduction in airflow for >10 sec) and all hypopneas (>30% reduction in airflow for 10 sec) 163 
associated with >4% oxygen (O2) desaturation divided by the total time where both flow and 164 
oximetry signals were valid; (2) the AHIall, which was defined as the sum of all apneas and all 165 
hypopneas identified plus events with visible reduction in airflow amplitude and presence of 166 
inspiratory flattening ending in breaths with normalization of airflow as a surrogate for arousal,24 167 
divided by the total time where there was a valid flow signal irrespective of O2 saturation; and, (3) 168 
mean saturation of oxygen (O2Sat) during the night. Although the systems used different 169 
techniques of oximetry measurement, we have previously shown that OSA indices between these 170 
two devices are highly correlated.22 Both systems and AHI indices have been compared with the 171 
recommended definitions of AHI.22 Reported total sleep time (TST) duration was assessed using 172 
one question: “During the past month, how many hours of sleep did you usually get each night?”  173 
 174 
Lumbar Puncture, CSF Collection and assays: 175 
The procedures for the NYU lumbar puncture (LP) are published.25;26 CSF amyloid beta (Aβ42), 176 
total-tau (T-tau) and tau phosphorylated at threonine 181 (P-tau) concentrations were measured 177 
using sandwich enzyme-linked immunosorbent assays (INNOTEST, Belgium). All assays were 178 
conducted at Sahlgrenska University Hospital. Batch wise rescaling of CSF Aβ42 was performed 179 
using linear regression with a reference batch. Before rescaling Aβ42, the coefficient of variation 180 
(CV) was 20%, and was reduced to 10% after rescaling. P-tau or T-Tau were not rescaled 181 
because the CV between batches was already relatively low (9%). CSF assays were done blind 182 
to clinical or sleep data. 183 
PiB scans: 184 
All subjects received PiB PET scans following standardized published procedures.27 185 
Parametric standardized uptake value ratio (SUVR) images were generated by normalizing PiB 186 
uptake by cerebellar grey matter uptake.28 PiB SUVR images were processed using automated 187 
regions-of-interest (ROI).27 These ROIs were used to sample AD-vulnerable brain regions from 188 
the PiB SUVR images, including: hippocampus (Hip), inferior parietal lobule (IPL), lateral temporal 189 
lobe (LTL), medial frontal gyrus (MFG), posterior cingulate cortex/precuneus (PCC), prefrontal 190 
cortex (PFC), occipital cortex (OCC), and thalamus (Thal). The cortical PiB meta-ROI retention 191 
mask (ADPiB-mask) was created by combining amyloid-vulnerable IPL, LTL, MFG, PCC, and PFC 192 
regions.29  193 
 194 









































Statistical analyses were performed using SPSS (version 23, SPSS, Inc., Chicago, IL). 196 
Baseline measures between OSA groups (normal, mild and moderate-severe) were examined 197 
based on AHI4% cutoff values (<5, 5-14.9 and ≥15 respectively) using ANOVA with post hoc 198 
Tukey tests for continuous variables and chi-square test for categorical variables. Regression-199 
based z-scores corrected for age, sex, race and education, derived from our normative sample,18 200 
were used for OSA group comparisons of cognitive variables (Logic 2, Animal Fluency [AF], 201 
Vegetable Fluency [VF]), Boston Naming Test [BNT], Digit Symbol Substitution Test [DSST], 202 
Trails Making Test-A [TMT-A] and Trails Making Test-B [TMT-B]); as well as for correlation 203 
analyses between annual rate of change of CSF Aβ42 and annual change in cognitive z-scores. 204 
For comparison between OSA severity groups, univariate analysis was used after adjusting for 205 
age, sex, BMI, ApoE4 and time interval between procedures.  206 
 To test whether normal elderly subjects with OSA showed evidence of positive PET/CSF AD 207 
biomarkers, first we calculated the correlation coefficients between AD biomarkers and OSA 208 
indices at cross-section. Direct and partial correlations were computed, the latter adjusting for 209 
relevant cofactors such as age, sex, BMI and ApoE4 status. A similar approach was used for 210 
longitudinal analyses using delta change in amyloid biomarkers. We decided to control for these 211 
factors a priori given the well documented association between decreased levels of CSF Aβ42, 212 
old age and the presence of ApoE4 allele. Male sex and obesity were similarly included as they 213 
are the most important risk factors for OSA, while female sex is also a well-known risk factor for 214 
AD.  215 
To calculate the annual rate of change of CSF Aβ42 or ADPiB-mask for each subject, we used 216 
the change in outcome from baseline to follow-up divided by the elapsed time from baseline to 217 
follow-up. We then applied a hierarchical linear regression, with annual rate of change of CSF 218 
Aβ42 or ADPiB-mask as dependent variables and OSA indices as independent, adjusting first for 219 
age, sex, BMI and ApoE4 status. To control for the type of sleep recording device, we included it 220 
as a covariate in the model. Due to the skewness and heavy tails in the distributions of ADPIB-221 
mask, non-parametric correlations were performed for comparisons between ADPiB-mask and 222 
OSA indices. Logarithm transformations were applied to continuous measures of Aβ42, P-Tau, T-223 
Tau, delta ADPiB-mask and AHI indices due to their right-skewed distributions. All statistical 224 
analyses were tested for violations of the model assumptions and any conflicts and resolutions 225 




Baseline demographics and sleep characteristics: 230 
Baseline demographic and raw values of sleep characteristics are summarized in Table 1. 231 
Among the 208 participants, 97 were free of OSA (AHI4%<5) and considered healthy controls, 232 
76 had mild OSA (AHI4% 5-15), and 35 had moderate to severe OSA (AHI4%>15). Within the 233 
moderate to severe group only, 14 subjects had an AHI4%>30 and 6 subjects had an AHI4%>45. 234 
OSA patients were more commonly male and older [X2 (2,n=208)=4.26, p=.11, F2,205=2.36, p=0.09  235 
respectively] and had significantly higher BMI than healthy controls (F2,206=9.67, p<.01). However 236 
it was not an obese group (mean BMI of 26.68±5.35 and only 14 subjects of the 208 with a 237 
BMI>35). Moreover, using repeated measures ANOVA, BMI within subjects did not change 238 
significantly at follow-up (F1,105=.68, n.s.). We did not find significant differences across healthy 239 
controls and OSA groups in years of education, hypertension, diabetes, cardiovascular, thyroid 240 
disease or ApoE4 status.  Excessive daytime sleepiness (EDS) was remarkably low in the entire 241 
sample (median ESS of 5, IQR 3,8), with only 19 subjects with an ESS>10. On univariate analysis 242 
there were no significant differences between OSA groups regarding TST. Overall TST was 243 










































Psychometric Assessment:  245 
Cross-sectional and longitudinal cognitive characteristics of all subjects are shown in Table 2. 246 
We did not find any statistically significant differences between OSA indices and cognition across 247 
healthy and OSA groups at baseline or longitudinally. To assess the relationship between 248 
longitudinal changes in CSF Aβ42 and cognitive performance, we performed Pearson correlation 249 
analyses comparing annual rate of change of CSF Aβ42 and annual change in cognitive z-scores. 250 
No statistically significant correlations were found: Logic 2 (r=-.12, n.s.), AF (r=.15, n.s.), VF 251 
(r=.09, n.s.), BNT (r=.006, n.s.), DSST (r=.16, n.s.), TMT-A (r=.001, n.s.) and TMT-B (r=-.08, n.s.). 252 
 253 
CSF and PET Assessment: 254 
From the 208 participants, 179 subjects performed a lumbar puncture (LP) at baseline. A 255 
second LP was obtained at follow-up in 104 subjects 2.42±0.88 years later. 86 subjects performed 256 
PiB scans at baseline.  A second PiB scan evaluation was obtained at follow-up in 34 subjects 257 
2.50±0.39 years later. 57 participants performed both the LP and the PET scans at baseline. 25 258 
participants performed the LP and PET scans at both baseline and follow-up (Figure 5). We will 259 
refer to participants with both baseline and follow-up biomarker data available as “completers”, 260 
whereas subjects with only baseline biomarkers data will be referred to as “non-completers”. 261 
There were no differences between completers and non-completers, in terms of (age [t=-.27, n.s.], 262 
sex [X2=.002, n.s.], BMI [t=.40, n.s.], MMSE [t=.00, n.s.], years of education [t=.17, n.s.], ApoE4 263 
status [X2=.93, n.s.], TST [t=1.18, n.s.], AHIall [t=.82, n.s.] or AHI4% [t=.88, n.s.]). Summary 264 
statistics of baseline, and annual changes of AD biomarkers are shown in Table 3. No significant 265 
associations were observed between annual changes in CSF Aβ42 and age (F1,93=2.23, p=.13, 266 
β=-1.68, 95% Confidence Interval [CI]= -.39 to .55, p=.13), sex (F1,93=.64, p=.42, β=13.64, 95% 267 
CI = -20.17 to 47.47, p=.42 ), BMI (F1,93=.16, p=.69,  β=-.61, 95% CI=-3.67 to 2.44, p=.69) or 268 
ApoE4 (F1,93=.42, p=.51, β=-11.35, 95% CI= -46.03 to 23.32, p=.51). At cross-section and 269 
longitudinally, we did not find any significant differences among the 3 OSA severity groups for 270 
CSF P-Tau or T-Tau. Similarly, no cross-sectional or longitudinal effects were found for CSF Aβ42 271 
across OSA severity groups using univariate analysis. No significant correlation between CSF 272 
Aβ42 and AHI indices were observed at cross-section.  273 
However, significant correlations were observed between longitudinal change in CSF Aβ42 274 
levels and AHIall/AHI4 (rho=-0.24, p<.05, rho=-0.23, p<.05, respectively) and after controlling for 275 
age, sex, BMI and ApoE4 (rho=-0.27, p<.05, rho=-0.24, p<.05, respectively). Significant 276 
associations were also observed between annual rate of change of CSF Aβ42 and AHI indices at 277 
baseline using hierarchical linear regression model (shown in table 4), including annual rate of 278 
change of CSF Aβ42 as dependent and AHI indices (lnAHI4 and lnAHIall) as independent 279 
variables, before (F1,92=5.41, p<.05, and F1,93=4.72, p<.05 respectively)  and after accounting for 280 
age, sex, BMI and ApoE4 (F1,88=4.26, p<.05 and F1,87=4.36, p<.05, respectively). The effect of the 281 
type of sleep recording device and TST were not significant, thus we excluded them from the final 282 
model. Figure 1 shows the relationship between delta change in CSF Aβ42 and the AHI indices at 283 
baseline. Sensitivity analyses were perfomed excluding 5 subjects whose baseline sleep 284 
evaluation was done after their first CSF measurements. Association between lnAHI4, lnAHIall, 285 
and annual delta CSF Aβ42 remained unchanged. 286 
 287 
Similarly, on univariate analysis no difference in ADPiB-mask was observed between OSA 288 
severity groups, and no significant correlation between ADPiB-mask and AHI indices were 289 
observed at cross-section. However, correlations were observed between longitudinal change in 290 
ADPiB-mask and AHIall or AHI4 (rho=0.374, p<.05, rho=0.302, p=0.09, respectively) after 291 
controlling for age, sex, BMI and ApoE4. Using the same hierarchical linear regression model as 292 
for CSF Aβ42, no statistically significant associations were observed between annual rate of 293 









































and AHI indices at baseline as independent variables after accounting for age, sex, BMI and 295 
ApoE4. LnAHIall and lnAHI4 were not associated with increases in ADPiB-mask most likely due to 296 
the small sample size as there was a trend for lnAHIall (F1,28=2.96, p=.09 and F1, 28=2.32, n.s. 297 
respectively). Figure 2 shows the relationship between delta change in ADPiB-mask and the AHIall 298 
index at baseline, both variables were corrected for normal distribution by log transformation.  299 
Further, we analyzed the association between longitudinal change in CSF Aβ42 and ADPiB-300 
mask. Using a Pearson correlation, a significant negative correlation between longitudinal change 301 
in CSF Aβ42 and ADPiB-mask was observed (r=-.44, p<.05). Using an ADPiB-mask SUVR ≥1.4 to 302 
define presence of brain amyloid deposition (PiB+),30-32 a secondary analysis performed only in 303 
the initial cross-sectional cases, revealed a significant difference between the slopes of PiB+ and 304 
PiB- cases (Figure 3). This was confirmed by the presence of an interaction between PiB status 305 
and lnAHI4% (F1,29=5.54, p<.05) as well as a positive trend between AHI4% and PiB uptake in 306 
PiB+ subjects (rho=0.67, p=.07). Similar findings were observed for AHIall (data not shown). 307 
Figure 3 shows the relationships between the AHI4% and PiB SUVR uptake when comparing 308 




The primary objective of this study was to determine if severity of OSA in cognitively normal 313 
elderly is associated with CSF and PET AD-biomarkers at cross-section and their longitudinal 314 
change across an approximate 2 year period. Our initial finding revealed that OSA was common 315 
and affected 53% of our cognitively normal community-dwelling cohort. Second, we demonstrated 316 
that baseline OSA severity was associated with two-year longitudinal decreases in CSF Aβ42 and 317 
a trend towards increases in cortical PiB-PET uptake. Such changes are potentially consistent 318 
with increased brain amyloid burden, which were also observed in our cohort (i.e., a negative 319 
correlation between longitudinal change in CSF Aβ42 and ADPiB-mask), suggesting that OSA may 320 
play a role in amyloid deposition in late-life. Moreover, the magnitude of these changes was higher 321 
than the one predicted by the presence of the ApoE4 allele alone (Table 4), which to date is 322 
considered the most important risk factor for sporadic AD. AHIall, which includes hypopneas 323 
associated with oxygen desaturation or arousals, was a better predictor of longitudinal increases 324 
in amyloid burden than AHI4%, which includes only hypopneas associated with 4% oxygen 325 
desaturation. This raises the possibility that sleep fragmentation is a more critical 326 
pathophysiological mechanism by which OSA contributes to AD risk. However, AHIall and AHI4% 327 
were highly correlated in our cohort (r=0.91, p<.01) and this study was unable to differentiate the 328 
individual effects of sleep fragmentation versus intermittent hypoxia.  329 
 330 
Although OSA severity was associated with increases in brain amyloid burden, it was not 331 
predictive of cognitive deterioration based on neuropsychological performance, which is in 332 
agreement with prior studies.33;34 This is not completely surprising given that the relationship 333 
between amyloid burden and cognition is probably nonlinear and dependent on additional factors 334 
such as tau pathology and microvascular changes. Low sensitivity of the neuropsychological tests 335 
used may have been another factor. Sensitivity could be increased in the future by employing 336 
cognitive tasks that are known to be sleep-dependent. 337 
Current evidence suggests that cognitive decline in AD is associated with decreases in CSF 338 
Aβ42 and increases in amyloid PET uptake.35 However, little is known about the temporal course 339 
of CSF Aβ42 in the preclinical or early stages of the disease, with some recent animal and human 340 
studies showing Aβ42 elevations prior to Aβ42 reductions,36;37 suggesting an intermediate stage of 341 
increased soluble Aβ levels prior to amyloid deposition. Interestingly, we and others have shown 342 







































are associated with increases in CSF Aβ levels, potentially as a consequence of increases in 344 
neuronal firing and/or decreases in amyloid clearance.38-41 It remains to be determined how 345 
universal a period of elevated CSF Aβ42 in humans is observed prior to a decline, but the above 346 
mentioned studies suggest that sleep disruption might be associated with elevations of CSF Aβ42 347 
which in chronic sleep disorders such as OSA could foster its aggregation and manifest as 348 
longitudinal decreases in CSF Aβ42 over time such as the one observed in our study. This 349 
hypothesis would also explain the absence of significant associations at cross-section. Whether 350 
OSA-related sleep fragmentation increases AD-risk through disruption of SWS or other sleep 351 
stages is unknown. The ends of apneas are associated with arousals or awakenings that prevent 352 
sleep42 and these are more commonly observed in NREM1-2 and REM sleep. Apneic episodes 353 
are less common in SWS, which has been associated with a higher respiratory arousal 354 
threshold43;44 as well as more stable breathing.45 However, the temporal course of SWA has been 355 
shown to be slower in mild OSA,46 while severe OSA patients show up to a 40% rebound in SWS 356 
duration during OSA treatment with CPAP,47 which suggest that changes in SWS quality may also 357 
be involved. However, a recent prospective study reported the association between decreased 358 
percentage of REM sleep and increased risk of dementia, implicating also REM sleep as a 359 
possible mediator for AD risk.48 In addition, actigraphy-assessed arousals and circadian rhythm 360 
disruption have also been shown to increase the risk of MCI/dementia in the elderly,49 indicating 361 
that the relationship between OSA-related sleep fragmentation and amyloid deposition might not 362 
be stage-specific.  363 
 364 
Another possible mechanism by which OSA might increase amyloid deposition is through 365 
impairment in the CSF-ISF exchange promoted by the glymphatic system40 resulting in decreased 366 
clearance of ISF Aβ42. This mechanism was suggested in a recent study of 31 controls and 10 367 
severe OSA middle-age subjects where neuronally derived proteins were decreased in the OSA 368 
group when compared to controls.40 The authors propose that elevations in the intrathoracic and 369 
intracranial pressure as well as a sudden pressure reversal at the end of the apnea would impede 370 
the glymphatic flow of metabolites from ISF into CSF.40 Another potential pathway of impairment 371 
of CSF-ISF exchange could be cerebral edema secondary to intermittent hypoxia, as proposed 372 
recently in a study in which severity of OSA correlated with increased volume and thickness of 373 
the left lateral prefrontal cortex as well as increased thickness of the right frontal pole, the right 374 
lateral parietal lobules, and the left posterior cingulate cortex.50 Similar findings were observed as 375 
brain volume reductions after six months of treatment with CPAP which also suggests the 376 
existence of brain edema in OSA.51  377 
 378 
Finally, the effects of OSA directly increasing ISF Aβ42 burden as suggested by some 379 
intermittent hypoxia animals models,52;53 or indirectly through other intermediate mechanisms 380 
such as oxidative stress, sympathetic activation, inflammation, hypercoagulability, endothelial 381 
dysfunction or metabolic dysregulation cannot be discarded although it is feasible that these and 382 
other consequences of OSA may decline with age10;54 and might not be as relevant in the elderly 383 
as in middle age. 384 
 385 
 Among participants with initial PiB+ scans at cross-section, Figure 3 suggest that a higher 386 
severity of OSA is associated with greater brain Aβ deposition, while no such association is found 387 
in participants with PiB- scans, implying that presence or absence of amyloid burden might act as 388 
a moderator in these relationships.  This would be in agreement with previous studies showing 389 
increased amyloid deposition associated with higher AHI indices in MCI patients but not in 390 
cognitively normal controls at cross-section.13 We did not observe this effect in the CSF sample 391 
when we compared amyloid positive vs. negative cases based on the NYU CBH CSF bank Aβ42 392 
cut-offs (i.e. CSF Aβ42 ng/ml <500), so this finding  should be interpreted with caution. It may be 393 









































accumulation has already occurred, leading to an acceleration of further Aβ deposition in a feed–395 
forward cycle13 (Figure 4) with OSA-related arousals worsening sleep quality and increasing 396 
amyloid deposition. In addition, 33/34 of the subjects that had PiB PET follow-up scans were PiB- 397 
at baseline, indicating that the observed longitudinal increases in PiB uptake were not dependent 398 
on amyloid status.  399 
 400 
Our observations are consistent with our hypothesis that there is an association between 401 
severity of OSA-related sleep fragmentation and longitudinal increase in amyloid burden in 402 
cognitively normal elderly. This implies that existing therapies for OSA such as CPAP could delay 403 
the progression to MCI or dementia in elderly with OSA, as was suggested by our previous 404 
epidemiological studies using the ADNI database11 and a recent cross-sectional study in which 405 
OSA patients showed lower CSF Aβ42 concentrations, as well as higher T-tau/Aβ42 ratio when 406 
compared to OSA-CPAP patients.15  407 
 The high prevalence of mild and moderate to severe OSA in cognitively normal elderly in 408 
asymptomatic adults undergoing screening for OSA as part of a protocol on memory and normal 409 
aging adds to the importance of these findings. Strengths of our study include that our community 410 
residing subjects were not recruited for the study based on sleep complaints, and thus should 411 
have been free of selection biases potentially affecting sleep-clinic based cohorts which typically 412 
include younger, more frequently male, obese and symptomatic (e.g. excessive daytime 413 
sleepiness, treatment resistant hypertension, etc.). We also utilized a state-of-the-art method for 414 
home-monitoring of OSA, as well as longitudinal standardized CSF and PET biomarkers. 415 
Potential weaknesses of the study were the relative short duration and the lack of longitudinal 416 
sleep data which did not allow us to test whether preclinical-AD brain lesions increase the risk for 417 
OSA, or the lack of a longer clinical assessment to test whether amyloid deposition is followed by 418 
cognitive decline to MCI or AD. Another limitation of the study was that not all subjects had a 419 
longitudinal follow up, although both completers and non-completers were not different in terms 420 
of sociodemographics, BMI, MMSE, AHIall or AHI4%. 421 
In summary, to our knowledge this study is the first to document that OSA is associated with 422 
longitudinal changes in amyloid burden in a sample of cognitively normal elderly. The implication 423 
of these findings is that we have identified a contribution of OSA in increasing the amyloid beta 424 
burden prior to significant cognitive decline. Our data support testing whether clinical interventions 425 
aimed at OSA, such as treatment with CPAP or dental appliances, could be implemented during 426 
the early phase in which tissue damage precedes clinical symptoms and neuronal dysfunction, to 427 
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Table 1: Baseline demographic and sleep characteristics of the subjects  
Characteristics All Normal Mild OSA Moderate-Severe 
OSA 
No. of Participants (%) 208 (100) 97 (46.63) 76 (36.53) 35 (16.82) 










































BMI (Kg/m2), median (IQR) 25.79 
(22.7,29.87) 






Age, years, mean ± SD    68.46 ± 
7.38 
67.56 ± 7.32 68.60 ± 7.19 70.68 ± 7.69 
Education, years, median (IQR) 17 (16, 18) 16.5 (16,18) 17 (16,18) 16 (14,19) 
Hypertension, number (%) 86 (41.3) 34 (35.1) 32 (42.1) 20 (57.1) 
Diabetes, number (%) 12 (5.8) 4 (4.1) 4 (5.3) 4 (11.4) 
Cardiovascular disease, number (%) 9 (4.3) 1 (1) 7 (9.2) 1 (2.9) 
Thyroid disease, number (%) 34 (16.3) 16 (16.5) 11 (14.5) 7 (20) 
APOE4 positive, number (%)  71 (34.1) 34 (35.1) 25 (32.9) 12 (34.3) 
AHI4% ,median (IQR) 5                 
(1.55, 11.40) 




25.00     
(19.3,37.00)* 
AHIall, median (IQR) 17            
(10.85, 24.00) 




39.00             
(31,57)* 
Mean O2 Saturation, median (IQR) 94.19        
(93.15, 95.6) 




93.47        
(92.1,94.5)* a 
ESS, median (IQR) 5 (3,8) 4 (3,7) 6 (3.5,8.5) 6 (4,9) 
TST,hours, median (IQR) 7 (6.5, 8) 7.48 (6.75,8) 7.00 (6.5,8) 7.50 (6.5,8) 
 
*,a Statistical significant difference between the groups. 
                                                                                                                                                                                                                       
Table 2: Cognitive characteristics of NYU cohort at baseline and follow-up evaluations 
 All (n=108) Normal (n=50) Mild OSA(n=43) Moderate-Severe 
OSA (n=15) 
MMSE baseline(mean±SD) 29.31 ±0.99 29.40±0.93 29.18±0.98 29.33±1.30 
MMSE follow-up 29.36±0.85 29.51±0.718 29.29±0.867 29.00±1.206 
CDR baseline 0±0 0±0 0±0 0±0 
CDR follow-up 0.010±0.071 0±0 0±0 0.083±0.19 
Animal fluency  (z-scores)  0.207±0.99 0.24±1.14 0.05±0.81 0.50±0.95 
Animal fluency  (delta change z-
scores) 
-0.23±0.87 -0.30±0.98 -0.20±0.85 -0.11±0.54 
Vegetable Fluency (z-scores) -0.042±1.1 -0.023±0.98 -0.14±1.28 0.15±0.96 
Vegetable Fluency (delta change z-
scores) 
-0.14±0.99 -0.39±0.87 0.087±1.08 -0.02±0.98 
Boston Naming Test (z-scores) -0.20±1.03 -0.10±1.06 -0.38±0.98 -0.017±1.07 
Boston Naming Test (delta change z-
scores) 
0.11±0.71 0.24±0.69 0.12±0.71 -0.28±0.69 
Logic 1 (z-scores) 0.19±0.96 0.11±1.0 0.24±0.90 0.29±1.05 
Logic 1 (delta change z-scores) -0.007±0.86    -0.03±0.87 -0.07±0.82 0.23±0.96 
Logic 2 (z-scores) 0.10±1.0 0.11±1.07        0.008±0.97 0.33±0.88 
Logic 2 (delta change z-scores) -0.012±0.75 0.042±0.8 -0.06±0.75 -0.04±0.67 
Trails Making Test-A time (z-scores) 0.062±1.06 -0.14±0.88 -0.33±1.04 0.12±0.89 
Trails Making Test-A time (delta 
change z-scores) 
0.048±0.88 0.025±0.14 0.127±0.7 -.093±1.03 
Trails Making Test-B time (z-scores) -0.17±0.96 -0.14±0.89 -0.33±1.04 0.12±0.9 
Trails Making Test-B time (delta 
change z-scores) 
-0.034±0.72 -0.007±0.65 -0.002±0.63 -0.19±0.64 










































DSST(delta change z-scores) 0.07±0.44 0.1±0.44 -.003±.45 0.18±0.37 
*Statistical significant difference between the groups. Lower scores represent worse cognitive function. 462 
Table 3: AD Biomarker characteristics  
 ALL 
(n=208) 
Normal (n=97) Mild OSA (n=76) Moderate-Severe 
OSA (n=35) 
CSF Aβ42 baseline        (n=179) 
Mean ± SD 




657.48 ± 224.79 
CSF Aβ42 annual change (n=104)                                  
Median (Interquartile range) 




26.97                         
(-29.99,66.71) 
-4.088                              
(-18.97,27.92) 
CSF P-tau baseline (n=179) 
Median (Interquartile range) 




43.55                 
(30,55) 
40.97                 
(31.71,49) 
CSF P-tau annual change (n=104) 
Mean ± SD 
1.42 ± 3.93 1.35 ± 3.18 0.73 ± 4.27 3.43 ± 4.90 
CSF T-tau baseline (n=179) 







248.14       
(174,343) 
CSF T-tau annual change (n=104) 
Mean ± SD 
8.24 ± 21.42 7.52 ± 
18.86 
5.85 ± 21.83 17.04 ± 27.53 
ADPiB PET baseline (n=86)                                      
Median (Interquartile range) 






1.06          
(1.01,1.14) 
ADPiB PET annual change (n=34)                                      
Median (Interquartile range) 
0.0005                            
(-0.009,0.014) 
-0.0020                  
(-
0.0095,0.0078) 




*Statistical significant difference between the groups. 463 
Dependent 
variable 




Model 1 -.008               .035 
Age -1.36 -3.67, .95 .24 
Sex 6.63 -27.72, 40.99 .70 
BMI .88 -2.36, 4.12 .59 
ApoE4 -15.54 -50.69, 8.81 .36 
Model 1 
+AHI4 .028 .046 AHI4 -13.35 -26.06, -.64 .04 
       
Model 1 -.008               .035 
Age -1.57 -3.86, .70 .17 
Sex 4.07 -30.36, 38.51 .81 
BMI 1.0 -2.27, 4.27 .54 
ApoE4 -17.89 -52.58, 16.79 .30 
Model 1 




 R2 ΔR2 Independent variables Β 95% CI p 
Annual  
Ln ΔPiB Model 1 -.068             .062 
Age .001 -.001, .004 .28 










































BMI -.001 -.004, .002 .37 
ApoE4 .01 -.026, .046 .36 
Model 1 
+AHI4 .134 .072 AHI4 .013 -.004, .03 .13 
       
Model 1 
   -.068               .062 
Age .001 -.001, .004 .25 
Sex .001 -.036, .038 .96 
BMI -.001 -.004, .002 .37 
ApoE4 .01 -.026, .046 .56 
Model 1 
+AHIall .151 .09 AHIall .026 -005, .057 .09 












































































Figure 3 500 
 501 


















































































Study flow chart showing a detailed breakdown of subjects based on AD 
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